Kidney cancer cases are increasing worldwide, creating a growing demand for effective and affordable targeted therapies. Axitinib Tablets 1 mg & 5 mg have become a preferred treatment option for patients diagnosed with advanced renal cell carcinoma (RCC).

Cordium Pharmaceuticals Pvt Ltd is committed to supplying high-quality oncology medicines to healthcare providers, distributors, hospitals, and importers across global markets.

With a focus on quality, compliance, and international accessibility, Cordium Pharmaceuticals helps improve cancer care outcomes in multiple countries.

What Are Axitinib Tablets?

Axitinib is a modern anti-cancer medicine that belongs to a class called vascular endothelial growth factor receptor (VEGFR) inhibitors.

It is primarily prescribed for adults with advanced kidney cancer, especially when previous treatments have become ineffective.

Unlike traditional chemotherapy, Axitinib selectively targets tumor blood supply pathways.

Why is Axitinib Becoming a Preferred Kidney Cancer Treatment?

Global oncology specialists increasingly recommend Axitinib because it offers:

• Precision-based targeted treatment
• Oral tablet convenience
• Flexible dosing options
• Reduced hospital dependency
• Improved progression-free survival outcomes
• Better disease management strategies

These advantages have contributed to rising search demand for Axitinib worldwide.

Conditions Treated With Axitinib Tablets

Axitinib is commonly used for:

Advanced Renal Cell Carcinoma (RCC)

The most common form of kidney cancer in adults.

Metastatic Kidney Cancer

When cancer has spread beyond the kidneys.

Combination Immunotherapy Protocols

Used alongside immunotherapy under specialist supervision.

Post-Treatment Disease Progression

For patients requiring second-line targeted therapy.

Available Strengths

Axitinib Tablets 1 mg

Recommended for:

• Dose reductions
• Sensitive patients
• Long-term treatment adjustment
• Personalized oncology protocols

Axitinib Tablets 5 mg

Commonly prescribed for:

• Standard treatment initiation
• Advanced RCC management
• Combination therapy plans

Mechanism of Action

Axitinib works by suppressing the development of new blood vessels that feed cancer cells.

It blocks:

• VEGFR-1
• VEGFR-2
• VEGFR-3

By restricting oxygen and nutrient supply, tumor growth slows significantly.

Key Benefits of Axitinib Therapy

Personalized Cancer Care

Supports individualized dosing schedules.

Oral Administration

No intravenous infusion required.

Improved Patient Convenience

Can be taken at home under medical supervision.

Evidence-Based Treatment

Widely used in international oncology practices.

Better Treatment Continuity

Allows ongoing disease management.

Typical Administration Guidelines

Important: Use only under an oncologist's supervision.

General guidance:

• Starting dose: 5 mg twice daily
• Tablets taken every 12 hours
• Can be consumed with or without food
• Swallow whole with water
• Dose modifications may be necessary

Do not alter doses without medical advice.

Possible Side Effects

Some patients may experience:

• Elevated blood pressure
• Fatigue
• Diarrhea
• Hoarseness
• Reduced appetite
• Weight loss
• Nausea
• Hand-foot syndrome
• Mouth irritation

Patients should undergo regular monitoring throughout treatment.

Why Global Buyers Choose Cordium Pharmaceuticals Pvt Ltd

Cordium Pharmaceuticals Pvt Ltd focuses on delivering quality-driven oncology solutions for international markets.

Our Strengths

✔ High-quality manufacturing standards

✔ International export support

✔ Reliable supply chain management

✔ Competitive pricing models

✔ Timely order fulfillment

✔ Oncology-focused portfolio

✔ Documentation and regulatory assistance

Countries We Export To

Cordium Pharmaceuticals Pvt Ltd actively serves oncology markets in:

Africa

• Kenya
• Nigeria
• Ghana
• South Africa

Asia

• Philippines
• Vietnam
• Uzbekistan
• Kazakhstan

Middle East

• United Arab Emirates
• Saudi Arabia

Western Markets

• United States
• United Kingdom